摘要
2型糖尿病(T2DM)是由多种因素导致的进展性慢性疾病,以血糖升高为主要特征,如血糖控制不佳,容易并发多种疾病,危害患者健康。钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂对常规血糖控制不佳的T2DM患者疗效显著。达格列净为我国首个上市的SGLT-2抑制剂,不仅可以控制血糖水平,对降低患者体重、心血管获益、保护肾脏等也有一定效果。但由于达格列净上市时间较短,其治疗T2DM的作用机制及不良反应等仍需进一步探究,以便为临床治疗提供指导。
Type 2 diabetes mellitus(T2DM)is a progressive chronic disease caused by a variety of factors,with elevated blood glucose levels as the main feature.If the blood glucose is poorly controlled,it is easy to complicate with multiple diseases,and endanger the health of the patients.Sodium-glucose cotransporter 2(SGLT-2)inhibitors have a significant effect on T2DM patients with poor glycemic control.Dagliflozin is the first SGLT-2 inhibitor which is marketed in China.It not only controls blood sugar levels,but also has a certain effect on reducing patient weight,cardiovascular benefits and protecting kidneys.However,due to the short marketing time of the drug,the mechanism of action and adverse reactions in the treatment of T2DM still need to be further explored,to provide guidance for the clinical treatment.
作者
赵香芳
常连庆
吕春雷
刘乃琴
王喻
ZHAO Xiangfang;CHANG Lianqing;LYU Chunlei;LIU Naiqin;WANG Yu(Cadre Ward Department,Tianjin Rehabilitation and Recuperation Center,Joint Logistics Support Force of Chinese People′s Liberation Army,Tianjin 300381,China)
出处
《医学综述》
2021年第4期783-787,共5页
Medical Recapitulate
关键词
2型糖尿病
钠-葡萄糖协同转运蛋白
达格列净
血糖
不良反应
Type 2 diabetes mellitus
Sodium-glucose cotransporter
Dapagliflozin
Blood glucose
Adverse reactions
